Gloucester Pharmaceuticals, Inc. to Present Positive Results from Multiple Studies of ISTODAX(R) at the American Society of Hematology Annual Meeting

Published: Nov 25, 2009

Bookmark and Share

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 – 8, 2009. ISTODAX, a novel histone deacetylase (HDAC) inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. Additionally, Gloucester is currently conducting a registration trial in peripheral T-cell lymphoma (PTCL) and studies of ISTODAX are being conducted in other hematologic and solid tumors. ISTODAX is not FDA approved for the treatment of PTCL or other indications.

Back to news